<SEC-DOCUMENT>0001104659-20-023392.txt : 20200220
<SEC-HEADER>0001104659-20-023392.hdr.sgml : 20200220
<ACCEPTANCE-DATETIME>20200220162130
ACCESSION NUMBER:		0001104659-20-023392
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200220
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200220
DATE AS OF CHANGE:		20200220

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		20635411

	BUSINESS ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm209345d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
February 20, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SYNTHETIC BIOLOGICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada</FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 34%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-12584</FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13-3808303</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction of<BR>
 incorporation)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File No.)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">9605 Medical Center Drive, Suite 270</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Rockville, MD 20850</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices
and zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: (301) 417-4364</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">N/A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section
12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; border: black 1pt solid; padding-left: 6.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title of each class</B></FONT></TD>
    <TD STYLE="width: 34%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading Symbol(s)</B></FONT></TD>
    <TD STYLE="width: 33%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name of each exchange on which registered</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 6.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock, par value $0.001 per share</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYN</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NYSE American</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">Emerging
growth company <FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 2.02  &nbsp;&nbsp;Results of Operations and Financial Condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On February 20, 2020, Synthetic Biologics, Inc., a Nevada corporation
(the &ldquo;Registrant&rdquo;) issued a press release that included financial information for the year ended December 31, 2019.
A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in the press
release is being furnished to the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) and shall not be deemed incorporated
by reference into any of the Registrant&rsquo;s registration statements or other filings with the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01&nbsp;&nbsp; Financial Statements and
Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)</FONT></TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits.</FONT></TD>
    <TD STYLE="width: 90%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><A HREF="tm209345d1_ex99-1.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Exhibit 99.1 Press Release issued by Synthetic Biologics, Inc., dated February 20, 2020</FONT></A></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 88%; border-collapse: collapse; margin-right: 1in">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: February 20, 2020</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYNTHETIC BIOLOGICS, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 25%">&nbsp;</TD>
    <TD STYLE="width: 12%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Steven A. Shallcross</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Steven A. Shallcross</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0in">Title: Chief Executive Officer <BR>
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and Chief Financial
        Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 10%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B><BR>
<B>Number</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 3%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 87%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><A HREF="tm209345d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">99.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tm209345d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release issued by Synthetic Biologics,
    Inc. dated February 20, 2020</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm209345d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm209345d1_ex99-1img001.jpg" ALT="T:\tm209345-1\tm209345-1_8kseq1">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics Reports 2019 Year
End Operational Highlights and Financial Results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>-- Received FDA Guidance Following
Type-C Meeting to Conduct a Phase 1b/2a Clinical Trial of </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>SYN-004 (ribaxamase) in Allogeneic
HCT Recipients; Enrollment Expected in Q2 2020 --</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>-- Enrollment is Ongoing in Phase
2b Investigator-Sponsored Clinical Study of SYN-010 </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>for the Treatment of IBS-C</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>-- Conference Call Today at 4:30 p.m.
(ET) --</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext"><B>Rockville,
MD, February 20, 2020 &ndash;</B></FONT> <U>Synthetic Biologics, Inc.</U> <FONT STYLE="color: windowtext">(NYSE American: SYN),
</FONT>a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal
(GI) diseases in areas of high unmet need, <FONT STYLE="color: windowtext">today provided a clinical programs update and reported
financial results for the year ended December 31, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;2019 was a highly eventful period
marked by significant progress as we continued to execute our strategy to advance and demonstrate the significant value of our
portfolio of GI and microbiome-focused clinical programs,&rdquo; stated Steven A. Shallcross, Chief Executive and Financial Officer.
 &ldquo;Following the announcement of our clinical trial collaboration with the Washington University School of Medicine in St.
Louis (&ldquo;Washington University&rdquo;) to advance SYN-004 in allogeneic hematopoietic cell transplant (HCT) patients, we held
an extremely productive Type-C meeting with the U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) to finalize the clinical
program parameters of a Phase 1b/2a clinical trial expected to begin next quarter. Allogeneic HCT recipients who receive broad-spectrum
IV beta-lactam antibiotics at onset of fever following conditioning chemotherapy are at high risk for <I>Clostridioides difficile</I>
infection (CDI), colonization by vancomycin-resistant <I>Enterococci </I>(VRE) and acute graft-versus-host-disease (aGVHD). We
believe SYN-004&rsquo;s unique mechanism of action designed to degrade IV beta-lactam antibiotics and prevent dysbiosis of the
gut microbiome has the potential to significantly improve outcomes for patients who undergo allogeneic HCT, an area of significant
unmet need.&rdquo;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Shallcross continued, &ldquo;Enrollment
in our investigator-sponsored Phase 2b clinical study for SYN-010 in breath-methane positive irritable bowel syndrome with constipation
(IBS-C) patients remains ongoing. We anticipate a data readout sometime during the first half of 2020 which we believe will further
fortify the established clinical data set for SYN-010 and support regulatory discussions to potentially simplify future registration
studies. Preclinical activities and toxicology studies are ongoing and remain on track to support a near-term Investigational New
Drug Application (IND) filing for our SYN-020 Intestinal Alkaline Phosphatase (IAP) program. We look forward to sharing important
updates and progress for this and all our GI and microbiome-focused clinical programs.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Clinical Development and Operational
Update</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Received official meeting minutes from FDA following a Type-C meeting held on December 2, 2018
at the Company&rsquo;s request to discuss the development of a Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic
HCT recipients. Based on the final meeting minutes,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Enrollment is expected to begin during the second quarter of 2020 contingent upon approval of the
clinical trial protocol by the Washington University School of Medicine&rsquo;s Institutional Review Board (IRB) and the FDA,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">The Phase 1b/2a clinical trial will comprise a single center, randomized, double-blind, placebo-controlled
clinical trial of oral SYN-004 (ribaxamase) in up to 36 evaluable adult allogeneic HCT recipients,</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">The goal of this clinical trial is to evaluate the safety, tolerability and potential absorption
into the systemic circulation (if any) of 150 mg oral SYN-004 (ribaxamase) administered to allogeneic HCT recipients who receive
an IV beta-lactam antibiotic to treat fever,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Clinical trial participants will be enrolled into three sequential cohorts and administered a
                                                                                                                             different study-assigned IV beta-lactam antibiotic. Eight participants in each cohort will receive SYN-004 (ribaxamase) and
                                                                                                                             four will receive placebo,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Safety and pharmacokinetic data for each cohort will be reviewed by an independent Data and Safety
Monitoring Committee, which will make a recommendation on whether to proceed to the next IV beta-lactam antibiotic;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Enrollment is ongoing in the Phase 2b investigator-sponsored clinical study of SYN-010 for the
treatment of IBS-C</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">The Phase 2b clinical trial is being conducted by the Medically Associated Science and Technology
(MAST) Program at Cedars-Sinai Medical Center and is a 12-week, placebo-controlled, double-blind, randomized clinical trial evaluating
two dose strengths of oral SYN-010 (21 mg and 42 mg) in up to 150 patients diagnosed with IBS-C,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">The primary objective for the study will be to determine the efficacy of SYN-010, measured as an
improvement from baseline in the weekly average number of complete spontaneous bowel movements (CSBMs) during the 12-week treatment
period for SYN-010 21 mg and 42 mg daily doses relative to placebo,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Secondary efficacy endpoints for both dose strengths of SYN-010 will measure changes from baseline
in abdominal pain, bloating, stool frequency as well as the use of rescue medication relative to placebo,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">A data readout is anticipated in 1H 2020,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Cedars-Sinai Medical Center and Synthetic Biologics are co-funding the study. The patent rights
covering the use of SYN-010 are owned by Cedars-Sinai Medical Center and are exclusively licensed by Cedars-Sinai Medical Center
to Synthetic Biologics;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Completed Pre-IND meeting with FDA to discuss advancement of SYN-020 (intestinal alkaline phosphatase)
into clinical trials targeting areas of significant unmet medical need, including enterocolitis associated with radiation therapy
for cancer</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Anticipate filing a US IND in Q2 2020;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Continued to exercise prudent cash management and financial stewardship to maintain cash runway
through at least the fourth quarter of 2020.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Year Ended December 31, 2019 Financial
Results</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses decreased
to $4.6 million for the year ended December 31, 2019, from $5.7 million for the year ended December 31, 2018. This decrease of
19% is due to decreased stock-based compensation expense related to forfeitures and decreased option grants, along with the reduction
of investor relations, consulting, registration, and legal costs. The charge relating to stock-based compensation expense was $0.3
million for the year ended December 31, 2019, compared to $1.0 million for the year ended December 31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses decreased
to $11.1 million for the year ended December 31, 2019, from $11.8 million for the year ended December 31, 2018. This decrease of
6% is primarily the result of lower SYN-004 (ribaxamase) indirect program costs for the year ended December 31, 2019, including
salary and related expense reductions resulting from the 2018 restructuring, and the fact that no clinical trial activity for SYN-004
(ribaxamase) was ongoing during the year ended December 31, 2019, offset by an increase in manufacturing and pre IND-enabling toxicology
study costs for SYN-020. Research and development expenses also include a charge relating to non-cash stock-based compensation
expense of $75,000 for the year ended December 31, 2019, compared to $1.1 million for the year ended December 31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total other income was $283,000 for the
year ended December 31, 2019, compared to other income of $4.2 million for the year ended December 31, 2018. Total other income
for the year ended December 31, 2019 is primarily comprised of interest income while total other income for the year ended December
31, 2018 is comprised of non-cash income of $4.1 million from the change in fair value of warrants. The decrease in the fair value
of warrants was due to the decrease in our stock price from December 31, 2017 to December 31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents on December 31,
2019 were $15.0 million, a decrease of $13.9 million from December 31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Conference Call</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Synthetic Biologics will hold a conference
call today, Thursday, February 20<FONT STYLE="font-weight: normal">, 2020, at 4:30 p.m. (EST).</FONT> The dial-in information
for the call is as follows, U.S. toll free: 1-888-347-5280 or International: +1 412-902-4280. Participants are asked to dial in
15 minutes before the start of the call to register. The call will also be webcast over the Internet at <U>https://www.webcaster4.com/Webcast/Page/1096/32979</U>.
An archive of the call will be available for replay at the same URL, <U>https://www.webcaster4.com/Webcast/Page/1096/32979</U>,
for 90 days after the call.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Synthetic Biologics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (NYSE American:
SYN) is a clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal
(GI) diseases in areas of high unmet need. The Company's lead clinical candidates are: (1) SYN-004 (ribaxamase) which is designed
to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome
damage, <I>C. difficile</I> infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR)
and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-010, which
is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable
bowel syndrome with constipation (IBS-C). The Company is also advancing SYN-020, an oral formulation of the enzyme intestinal
alkaline phosphatase (IAP) to treat both local GI and systemic diseases. For more information, please visit Synthetic Biologics'
website at <U>www.syntheticbiologics.com</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This release contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements
can be identified by terminology such as &quot;may,&quot; &quot;should,&quot; &quot;potential,&quot; &quot;continue,&quot; &quot;expects,&quot;
 &quot;anticipates,&quot; &quot;intends,&quot; &quot;plans,&quot; &quot;believes,&quot; &quot;estimates,&quot; and similar expressions,
and include statements regarding anticipated initiation of a Phase 1b/2a investigator-sponsored clinical study in allogeneic HCT
patients in the second quarter of 2020, the potential of SYN-004&rsquo;s unique mechanism of action designed to degrade IV beta-lactam
antibiotics and prevent dysbiosis of the gut microbiome to significantly improve outcomes for patients who undergo allogeneic
HCT, an area of significant unmet need, anticipated data readout for the investigator-sponsored Phase 2b clinical study for SYN-010
during the first half of 2020, the data readout further fortifying the established clinical data set for SYN-010 and supporting
regulatory discussions to potentially simplify future registration studies, anticipated IND filing for SYN-020 in the first half
of 2020. These forward-looking statements are based on management&rsquo;s expectations and assumptions as of the date of this
press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause
actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking
statements. Important factors that could cause actual results to differ materially from current expectations include, among others,
a failure to receive the necessary regulatory approvals for commercialization of Synthetic Biologics&rsquo; therapeutics, a failure
of Synthetic Biologics&rsquo; clinical trials, and those conducted by investigators, for SYN-004 and SYN-010 to be commenced or
completed on time or to achieve desired results and benefits, a failure of Synthetic Biologics&rsquo; clinical trials to continue
enrollment as expected or receive anticipated funding, a failure of Synthetic Biologics to successfully develop, market or sell
its products, Synthetic Biologics&rsquo; inability to maintain its material licensing agreements, or a failure by Synthetic Biologics
or its strategic partners to successfully commercialize products and other factors described in Synthetic Biologics&rsquo; most
recent Form 10-K and its other filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information
in this release is provided only as of the date of this release, and Synthetic Biologics undertakes no obligation to update any
forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required
by law.&nbsp;&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (Corporate and
Investors)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vincent I. Perrone, Director Corporate Communication, (240)
660-2000, <U>info@syntheticbiologics.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ogilvy (Media)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gregory Kelley, Senior Vice President, (404) 836-2302, <U>gregory.kelley@ogilvy.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>- Financial Tables Follow -</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I></I></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Synthetic Biologics, Inc. and Subsidiaries</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: center">(in thousands, except share and per share amounts)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font: bold 10pt Times New Roman, Times, Serif">Consolidated Balance Sheets</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">15,045</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">28,918</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Prepaid expenses and other current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,381</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">593</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Property and equipment, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">367</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">607</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Right of Use Asset</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">419</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Deposits and other assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">23</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">23</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total Assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">17,235</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">30,141</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Liabilities and Stockholder&rsquo;s Equity (Deficit)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Total liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,748</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,686</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Series A Convertible Preferred Stock</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12,544</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12,296</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Synthetic Biologics, Inc. and Subsidiaries Equity (Deficit)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,057</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">14,159</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Stockholders&rsquo; Equity (Deficit)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">17,235</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">30,141</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Condensed Consolidated Statements of Operations</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">For the years ended<BR> December 31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Operating Costs and Expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; width: 74%; text-align: left">General and administrative</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">4,580</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">5,727</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Research and development</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">11,083</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">11,844</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total Operating Costs and Expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">15,663</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">17,571</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Loss from Operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(15,663</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(17,571</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Other Income</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Change in fair value of warrant liability</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,083</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Interest income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">283</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">67</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total Other Income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">283</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,150</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Net
Loss </B></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(15,380</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(13,421</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Net Loss Attributable to Non-controlling Interest</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(77</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(54</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Net
                                         Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries</B></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(15,303</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(13,367</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Series
    A Preferred Stock Dividends</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(248</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(243</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Series
    B Preferred Stock Dividends</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(525</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(11,681</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net Loss Attributable to Common Stockholders</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(16,076</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(25,291</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net Loss Per Share - Basic and Dilutive</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.98</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(4.06</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Weighted average number of common shares outstanding - Basic and Dilutive</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">16,438,201</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">6,232,442</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"># # #</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm209345d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm209345d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !3 /X# 2(  A$! Q$!_\0
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MXCM?VF_$6L>$=8LDU&&\?3E>SGMR!(LA+7.W &#STQSC%=I\3?V'?#_[#/\
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9HH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
